Valuation: Roche Holding AG

Capitalization 255B 328B 278B 240B 448B 31,242B 452B 3,022B 1,180B 14,879B 1,230B 1,205B 51,491B P/E ratio 2026 *
16.9x
P/E ratio 2027 * 15.7x
Enterprise value 265B 341B 290B 250B 467B 32,535B 470B 3,147B 1,228B 15,495B 1,281B 1,254B 53,622B EV / Sales 2026 *
4.23x
EV / Sales 2027 * 3.94x
Free-Float
88.75%
Yield 2026 *
3.14%
Yield 2027 * 3.22%
1 day+1.21%
1 week-0.97%
Current month-0.97%
1 month-0.10%
3 months-10.20%
6 months+13.05%
Current year-3.93%
1 week 313
Extreme 313
325.8
1 month 312
Extreme 312
326.7
Current year 291
Extreme 291
374.9
1 year 243.9
Extreme 243.9
374.9
3 years 212.9
Extreme 212.9
374.9
5 years 212.9
Extreme 212.9
404.2
10 years 206.35
Extreme 206.35
404.2
Manager TitleAgeSince
Chief Executive Officer 51 14/03/2023
Director of Finance/CFO 59 05/06/2011
Chief Operating Officer - 30/09/2025
Director TitleAgeSince
Director/Board Member 68 31/12/1995
Chairman 59 14/03/2023
Director/Board Member 73 02/03/2015
Change 5d. change 1-year change 3-years change Capi.($)
+1.21%-0.97%+22.40%+12.53% 324B
+1.95%-0.10%+27.98%+122.02% 846B
+0.05%-1.24%+43.66%+37.54% 533B
+0.61%-2.58%+6.69%+38.33% 356B
+1.18%-0.07%+31.86%+14.23% 282B
+0.30%-1.90%+25.07%+23.67% 278B
-0.09%-1.62%+38.36%-5.33% 275B
+3.34%+7.91%-32.48%-47.44% 203B
-0.64%+1.77%+19.96%+41.89% 179B
+1.67%+0.63%+28.61%+69.66% 163B
Average +0.99%-0.63%+21.21%+30.71% 343.84B
Weighted average by Cap. +1.08%-1.12%+24.64%+46.32%

Financials

2026 *2027 *
Net sales 62.74B 80.74B 68.51B 59.16B 110B 7,692B 111B 744B 290B 3,663B 303B 297B 12,677B 65.33B 84.06B 71.33B 61.6B 115B 8,009B 116B 775B 302B 3,814B 315B 309B 13,200B
Net income 14.79B 19.03B 16.15B 13.94B 26.01B 1,813B 26.22B 175B 68.46B 863B 71.4B 69.9B 2,988B 15.8B 20.33B 17.26B 14.9B 27.79B 1,937B 28.01B 187B 73.15B 923B 76.29B 74.69B 3,193B
Net Debt 10.54B 13.57B 11.51B 9.94B 18.54B 1,293B 18.69B 125B 48.81B 616B 50.9B 49.83B 2,130B 2.71B 3.49B 2.96B 2.56B 4.77B 333B 4.81B 32.18B 12.56B 158B 13.1B 12.83B 548B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
07/05/26 315.30 CHF -0.94% 590,249
11/05/26 319.40 CHF +1.30% 724,136
08/05/26 315.30 CHF -0.94% 590,249
07/05/26 318.30 CHF -1.12% 690,846
06/05/26 321.90 CHF +1.07% 806,860
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
319.40CHF
Average target price
360.76CHF
Spread / Average Target
+12.95%

Quarterly revenue - Rate of surprise